Athersys (ATHX) : 3 investment research analysts covering Athersys (ATHX) have an average price target of $4.33 for the near short term. The highest target price given by the Brokerage Firm to the stock is $10 and the lowest target is $1 for the short term. Analysts expect the variance to be within $4.93 of the average price.
Athersys (ATHX) has an average broker rating of 1.67, which is interpreted as a Buy, as rated by 3 equity analysts. Nonetheless, 2 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.
Athersys (NASDAQ:ATHX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $1.92 and $1.91 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $2.00. The buying momentum continued till the end and the stock did not give up its gains. It closed at $1.94, notching a gain of 1.57% for the day. The total traded volume was 259,206 . The stock had closed at $1.91 on the previous day.
Athersys Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Companys MultiStem cell therapy is being evaluated in multiple clinical trials. Its current clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease and other conditions. It is also identifying and developing small molecule compounds with applications in indications, such as obesity, related metabolic conditions and neurological conditions. It is engaged in the preparation stages for clinical studies in other targeted areas, including the treatment of ARDS. Its current programs include Ischemic Stroke, Acute Myocardial Infarction, Acute Respiratory Distress Syndrome, Hematopoietic Stem Cell Transplant/GvHD and Inflammatory Bowel Disease. In addition to the programs, it is also conducting or supporting clinical activity in other areas, such as solid organ transplant.